Cardinal Health forecasts full-year profit above estimates on specialty drug strength
Cardinal Health forecast fiscal 2027 adjusted profit per share of $12.40 to $12.60, above the $12.04 average estimate, citing strength in specialty drugs. In Q4, adjusted profit was $2.91 per share versus $2.42 expected, while revenue rose 6% to $63.67B, below $65.03B. The company also plans $1B share repurchases in FY2027.
How this was made
The 30-second read
Why it matters
The company’s fiscal 2027 adjusted EPS forecast ($12.40-$12.60) is above consensus ($12.04) after an adjusted Q4 EPS beat, which can re-rate near-term earnings expectations and support buyback plans.
Market read
Traders can update earnings models immediately using the new fiscal 2027 EPS range, Q4 adjusted EPS beat, and the stated $1B FY2027 share repurchase outlook.
What to watch
The article does not quantify how much of the guidance strength is driven by the AdaptHealth/Strive tuck-ins versus organic specialty demand, which could affect forward risk.
Background
Cardinal Health is a major US drug distributor with a large Pharmaceutical and Specialty Solutions segment, currently benefiting from specialty drug demand.
Ticker impact
Cardinal Health guided fiscal 2027 adjusted EPS to $12.40-$12.60 after Q4 EPS beat, citing sustained specialty drug demand.
Likely positive bias for shares and sector read-through into specialty drug distribution demand.
The article provides explicit 2027 EPS guidance above consensus and a Q4 adjusted EPS beat, both direct drivers for earnings expectations and valuation.
Market effects
Reinforces the specialty drug and biosimilars demand narrative for US drug distributors, potentially supporting peers’ earnings expectations.
Limited, primarily US-focused distributor demand signal.
Moderate, as specialty drug distribution demand is a cross-market theme but the disclosure is company-specific.
Counterpoint
Revenue missed expectations in Q4, so the EPS outperformance may reflect margin or mix rather than broad top-line strength.
Key entities
- companyCardinal Health
Forecasts fiscal 2027 adjusted EPS above estimates after Q4 profit beat, citing specialty drug strength.
- companyAdaptHealth
Sold diabetes health business and Strive Medical to Cardinal in tuck-in deals expanding home care and diabetes/urology reach.
- companyStrive Medical
Included in Cardinal’s acquisition to expand urology market position and home care capabilities.
